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1. INTRODUCTION 
1.1   An Overview of Sustained Release Dosage Forms 
   Sustained release tablets and capsules are commonly taken only once or twice 
daily, compared with counterpart conventional forms that may have to take three or four 
times daily to achieve the same therapeutic effect. Typically, sustained release products 
provide an immediate release of drug that promptly produces the desired therapeutic 
effect, followed by gradual release of additional amounts of drug to maintain this effect 
over a predetermined period. The sustained plasma drug levels provide by sustained 
release products often times eliminates the need for night dosing, which benefits not only 
the patients but the care given as well.1 
The basic rationale of a sustained drug delivery system is to optimize the 
Biopharmaceutical, Pharmacokinetic and Pharmaco dynamic properties of a drug in such 
a way that its utility is maximized through reduction in side effects and cure or control of 
condition in the shortest possible time by using smallest quantity of drug, administered by 
the most suitable route. 
 The novel system of drug delivery offer a means of improving the therapeutic 
effectiveness of incorporated drugs by providing sustained, controlled delivery and / or 
targeting the drug to desired site. The goal of any drug delivery system is to provide a 
therapeutic amount of drug to the proper site in the body to achieve promptly and then 
maintain the desired drug concentration. There is a continuously growing interest in the 
pharmaceutical industry for sustained release oral drug delivery systems. There is also a 
high interest for design a dosage formulation that allows high drug loading, particularly 
for actives with high water solubility. Oral route has been the most popular and 
successfully used for sustained delivery of drugs because of convenience and ease of 
administration, greater flexibility in dosage form design and ease of production and low 
cost of such a system. 
 The sustained release systems for oral use are mostly solid and based on 
dissolution, diffusion or a combination of both mechanisms in the control of release of 
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drugs. In this type of dosage forms, a sufficient amount of drug is initially made available 
to the body to cause a desired pharmacological response. 
When a conventional dosage form is administered, the concentration of drug in 
the blood stream will attain a “therapeutic range” necessary for the action of the drug. 
This therapeutic range would be maintained for some time and finally the concentration 
drops below this range rendering the drug therapeutically inactive. An ideal drug delivery 
system involves two prerequisites. It should deliver the drug at a rate desired by the needs 
of the body and over the period of treatment. 
This necessitates steady state blood levels or tissue levels that are therapeutically 
effective and nontoxic for an extended period of time. It should channel the active entity 
to the site of action. Advanced research in pharmaceutical technology would find several 
controlled release dosage forms in the market. These products have been identified by 
various names as “sustained release”, “prolonged release”, “controlled release”, “timed 
release”, and “delayed release”. 
Fig No: 1 An hypothetical plasma concentration-time profile from conventional, 
multiple dosing and single doses of sustained and controlled delivery formulations 2 
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1.2   Selection Criteria of Drug for SR  Formulation  
            Half-life should be 2-8 hours. 
It should not undergo extensive first –pass metabolism. 
It should be stable in GIT. 
Compounds with high partition coefficient are better to choose. 
Lower limit of solubility of a drug is 0.1 mg/ml.  
Drugs absorbed throughout GIT are better candidates. 
 
Table.No:1 Characteristics of Drugs Unsuitable for oral Sustained             
Release Forms 
Characteristics Drugs 
Not effectively absorbed in the lower 
intestine 
Riboflavin, Ferrous salts 
Absorbed and excreted rapidly short 
biologic half-lives (<1hr) 
Penicillin G, Furosemide 
Long biological half-lives (>12hr) Diazepam, Phenytoin 
Large doses required (>1g) Sulphonamides 
Cumulative action and undesirable side 
effects, Drugs with low therapeutic 
indices 
Phenobarbital, Digitoxin 
Precise dosage titrated to individual is 
require 
Anticoagulants,cardiac glycosides 
No clear advantage for sustained 
release formulation 
Griseofulvin. 
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1.3  Terminology 
In the past, many of the terms used to refer to therapeutic systems of controlled 
and sustained release have been used in an inconsistent and confusing manner. Although 
descriptive terms such as “timed release” and “prolonged release” give excellent 
manufacturer identification, they can be confusing to health care professionals. Several 
descriptions have been given to sustained and controlled release3. Defined sustained 
release as “Any dosage form that provide medication over an extended time” and 
controlled release as “Any dosage form which is able to provide some actual therapeutic 
control, whether this can be of temporal nature, spatial nature, or both”. In other words, 
controlled release system attempts to control drug concentrations in the target tissue. This 
correctly suggests that there are sustained release systems that cannot be considered 
controlled release systems. The terminologies, which are frequently used in practice, are 
given below: 
• Zero-order release 
• Sustained release 
• Controlled release 
• Prolonged release 
• Repeat action tablets 
• Delayed-release systems 
In general, the goal of a sustained release dosage form is to maintain therapeutic 
blood or tissue levels of the drug for an extended period. This is usually achieved by 
attempting to obtain zero-order release from the dosage form. Zero-order release 
constitutes drug release from the dosage that is independent of the amount of drug in the 
delivery system. Sustained release systems generally do not attain this type of release and 
usually try to obtain zero-order release by providing drug in a slow first order fashion. 
Systems that are designated as prolonged release can also be considered as attempts at 
achieving sustained release delivery. Repeat action tablets are an alternative method of 
sustained release in which multiple doses of a drug are contained with in a dosage form, 
and each dose is released at periodic interval. Delayed release systems, in contrast, may 
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not be sustaining, since often the function of these dosage form is to maintain the drug 
within the dosage form for some time before release. Commonly, the release rate of drug 
is not altered and does not result in sustained delivery once drug release has begin. 
Enteric coating tablets are an example of this type of dosage form4 . 
Controlled release, although resulting in a zero order delivery system, may also 
incorporate methods to promote localization of the drug at an active site. In some cases, a 
controlled release system will not be sustaining, but will be concerned strictly with 
localization of the drug. Site specific systems and targeted delivery systems are the 
descriptive terms used to denote this type of delivery control. 
The goal of controlled release systems is to achieve a delivery profile that would 
yield a high blood level of the drug over a long period of time.  With traditional tablets, 
the drug level in the blood follows the profile shown in figure 1 in which level rises after 
each administration of the drug and then decreases until the next administration. The key 
point with traditional drug administration is that the blood level of the agent should 
remain between a maximum value, which may represent toxic level, and a minimum 
value, below which the drug is no longer effective. In controlled drug delivery systems 
designed for long term administration the drug level in the blood follow the profile shown 
in figure 1 remaining constant, between the desired maximum and minimum, for an 
extended period of time. 
Several types of modified-release drug products are recognized 4.  
• Extended release drug products: A dosage form that allows at least a twofold 
reduction in dosage frequency as compared to that drug presented as an 
immediate-release (conventional) dosage form. Examples of extended-release 
dosage forms include controlled-release, sustained-release, and long-acting drug 
products.  
• Delayed release drug products: A dosage form that releases a discrete portion or 
portions of drug at a time or at times other than promptly after administration, 
although one portion may be released promptly after administration. Enteric-
coated dosage forms are the most common delayed-release products.  
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• Targeted release drug products. A dosage form that releases drug at or near the 
intended physiologic site of action. Targeted-release dosage forms may have 
either immediate or extended release characteristics. 
• Controlled release drug product: was previously used to describe various types 
of oral extended release-rate dosage forms, including sustained release, 
sustainedaction, prolonged action, long action, slow release, and programmed 
drug delivery.  
1.4 Advantages of sustained release formulations 4, 5 
 Sustained release formulations have many advantages over traditional, immediate                 
release products. 
• Improved patient convenience and compliance due to less frequent drug 
administration. 
• Reduction in fluctuation in steady state levels and therefore better control of 
disease condition and reduced intensity of local or systemic side effects. 
• Increased safety margin of high potency drugs due to better control of plasma 
levels. 
• Maximum utilization of drug enabling reduction in total amount of dose 
administered. 
• Reduction in health care costs through improved therapy, shorter treatment 
period, less frequency of dosing and reduction in personnel time to dispense, 
administer and monitor patients . 
1.5. Disadvantages of sustained release formulations 
• Decreased systemic availability in comparison to immediate release conventional 
dosage forms; this may be due to incomplete release, increased first-pass 
metabolism, increased instability, insufficient residence time for complete release, 
site specific absorption, pH depent solubility, etc. 
• Poor in vitro-in vivo correlation. 
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• Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus, increased risk of 
toxicity. 
• Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions. 
• Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths. 
• Higher cost of formulation. 
1.6. Factors influencing the design and performance of sustained release 
products                 
The type of delivery system and route of administration of the drug presented in 
sustained drug delivery system may depend upon two properties. They are: 
a) Physicochemical properties of drugs 
b) Biological factors. 
a) Physicochemical Properties  
1. Dose size  
For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general a single dose of 0.5 to 1gm is considered maximum . 
1. Ionization, pka & Aqueous Solubility  
 The pH Partition hypothesis simply states that the unchanged form of a drug 
species will be preferentially absorbed through many body tissues. Therefore it is 
important to note the relationship between the pKa of the compound and its absorptive 
environment. For many compounds, the site of maximum absorption will also be the area 
in which the drug is least soluble. 
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3. Partition coefficient                   
           The compounds with a relatively high partition coefficient are predominantly lipid 
soluble and easily penetrate membranes resulting high bioavailability. Compounds with 
very low partition coefficient will have difficulty in penetrating membranes resulting 
poor bioavailability. Furthermore, partitioning effects apply equally to diffusion through 
polymer membranes. 
4. Drug Stability  
           The drugs, which are unstable in stomach, can be placed in a slowly soluble form 
and their release delayed until they reach the small intestine. However, such a strategy 
would be Determined for drugs that either are unstable in the small intestine (or) undergo 
extensive gut wall metabolism, as pointed out in the decrease bioavailability of some anti 
cholinergic drugs from controlled /sustained release formulation. 
b) Biological Factors 
Pharmacokinetic Characteristics  
1. Biological Half-Life  
           Therapeutic compounds with half-life less than 8 hrs are excellent 
candidates for sustained release preparations. Drugs with very short half-life (less than 2 
hrs) will require excessively large amounts of drug in each dosage unit to maintain 
controlled effects. Thus forcing the dosage form itself to become too large to be 
administered. Compounds with relatively long half-lives, generally greater than 8 hrs are 
not used in the sustained release dosage forms, since their effect is already sustained and 
also GI transit time is 8-12 hrs. So the drugs, which have long half life and short half life, 
are poor candidates for sustained release dosage forms4. 
2. Absorption  
The characteristics of absorption of a drug can greatly affect its suitability as a 
sustained release product. Drugs which are absorbed by specialized transport process 
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(carrier mediated) and drug absorption at special sites of the gastrointestinal tract 
(Absorption Window) are poor candidates for sustained release products. 
3. Metabolism 
The metabolic conversion of a drug to another chemical form usually can be 
considered in the design of a sustained release system for that drug. As long as the 
location, rate and extent of metabolism are known and the rate constant for the process  
are not too large, successful sustained release products can be developed. 
Pharmacodynamic Characteristics 
1. Therapeutic Range 
A drug candidate for controlled delivery system should have a therapeutic range 
wide enough such that variations in the release rate do not result in a concentration 
beyond this level. 
2. Therapeutic Index   
The release rate of a drug with narrow therapeutic index should be such that the 
plasma concentration attained is within the therapeutically safe and effective range. This 
is necessary because such drugs have toxic concentration nearer to their therapeutic 
range. Precise control of release rate of a potent drug with narrow margin of safety is 
difficult. A drug with short half-life and narrow therapeutic index should be administered 
more frequently than twice a day. One must also consider the activity of drug metabolites 
since controlled delivery system controls only the release of parent drug but not its 
metabolism. 
2. Plasma concentration response 
 Drugs such as reserpine whose pharmacological activity is independent of 
its concentration are poor candidates for controlled release systems. 
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1.7 Polymers used in Sustained Release Formulations                                                                    
 Polymers have gained importance in pharmaceutical industry as both drug 
encapsulants and vehicles of drug carriage; either protecting an active agent during its 
passage through the body until its release, or controlling its release. Polymers in drug 
delivery are classified into 
1.7.1 Bio-degradable polymers 
• Natural: Alginates, Guar gum, Chitosan, Gelatin, Xanthan gum and  Carrageenan. 
• Synthetic: Polylactic acid, Polycaprolactone, Polyglycolic acid, Poly 
lacticglycolic acid and Polyanhydride. 
1.7.2 Bio absorbable polymer: Polyethylene glycol and polyvinylpyrrolidone 
1.7.3 Bio nondegradable polymers: Hydroxy propyl methyl cellulose, ethyl cellulose, 
Acrylic Polymers, Silicone elastomers, Poly vinyl chloride, Polyurethanes and  polyethy 
vinyl acetate polymers. 
 The greatest advantage of biodegradable polymers is that they are broken down 
into biologically acceptable molecules that are metabolized and removed from the body 
via normal metabolic pathways. However, biodegradable materials degradation by 
products that must be tolerated with little or no adverse reactions within the biological 
environment 5, 6.  
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1.8 Oral Drug Delivery Systems7 
Among all routes of administration, the oral route has been most popular and 
successful.  
Designs: Oral controlled delivery systems can be broadly divided into following 
categories, based on their mechanism of drug release: 
1. Dissolution-controlled release 
a. Encapsulation dissolution control 
b. Matrix dissolution control 
2. Diffusion-controlled release 
a. Reservoir devices 
b. Matrix devices 
3. Ion exchange resins 
4. Osmotic controlled release 
Dissolution controlled release 
Dissolution controlled release can be obtained by slowing the dissolution rate of a 
drug in the GI medium, incorporating the drug in an insoluble polymer, and coating drug 
particles or granules with polymeric materials of varying thickness. The rate limiting step 
for dissolution of a drug is the diffusion across an aqueous boundary layer. The solubility 
of the drug provides the source of energy for drug release, which is countered by the 
stagnant fluid diffusional boundary layer. The rate of dissolution (dm/dt) can be 
approximated by below. 
                                                        dm/dt = ADS/h 
S = Aqueous solubility of the drug concentration 
A = Surface area of the dissolving particle or tablet concentration 
D = Diffusivity of the drug 
h = Thickness of the boundary layer. 
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 Drug delivery using rate of dissolution as a controlled release mechanism can be 
achieved by encapsulation of a drug-polymer matrix with a relatively insoluble polymeric 
membrane. The coated beads can be compressed into tablets or capsulated, as was done 
with the spansule products. Since the time required for the membrane coat to dissolve is a 
function of membrane thickness, granules with varying thicknesses can be employed to 
achieve sustained release of the drug. 
 One of the most common approaches used to achieve sustained release is to 
incorporate a drug in a hydrophobic matrix such as wax, polyethylene, polypropylene and 
ethylcellulose; or a hydrophilic matrix such as hydroxypropylcellulose, 
hydroxylpropylmethylcellulose, methylcellulose and sodium carboxymethylcellulose. 
The rate of drug availability is controlled by the rate of penetration of the dissolution 
fluid into the matrix. It depends on the porosity of the compressed structure. In the case 
of a water-soluble drug in a hydrophobic matrix, the rate of drug availability. 
Diffusion Controlled Release 
Diffusion of a drug molecule through a polymeric membrane forms the basis of 
these controlled drug delivery systems. Similar to the dissolution controlled systems, the 
diffusion controlled devices are manufactured either by encapsulating the drug particle in 
a polymeric membrane or by dispersing the drug in a polymeric matrix. Unlike the 
dissolution-controlled systems, the drug is made available as a result of partitioning 
through the polymer. In the case of a reservoir type diffusion controlled device, the rate 
of drug released (dm/dt) can be calculated using below. 
dm/dt = ADK∆C/l 
A = Area 
D = Diffusion coefficient 
K = Partition coefficient of the drug between the drug core and the membrane 
l = Diffusional pathlegth and ∆C = Concentration difference across the membrane. 
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 Another configuration of diffusion controlled systems includes matrix devices, 
which are very common because of ease of fabrication. Diffusion control involves 
dispersion of drug in either a water-insoluble or a hydrophilic polymer. The release rate is 
dependent on the rate of drug diffusion through the matrix but not on the rate of solid 
dissolution. Below describes the amount of drug released from the systems as derived by 
Higuchi 
Q = [Dε/ τ (2C - εS) St]1/2 
Q = Amount of drug released per unit surface area 
D = Diffusion coefficient of the drug in the release media 
ε = Porosity 
τ = Tortuosity of the matrix 
S = Solubility of the drug in the release media 
C = Concentration of the drug in the tablet 
Osmotically controlled release 
In the early 1970s, Developed an elementary osmotic pump (EOP) to achieve 
controlled drug delivery. The delivery of the drug from the system is controlled by 
solvent influx across a semipermeable membrane, which in turn carries the drug outside 
through a laser drilled orifice. The osmotic and hydrostatic pressure differences on either 
side of the semipermeable membrane govern fluid transport into the system. Therefore, 
the rate of drug delivered from the system is dependent on the osmotic pressure of the 
formulation (pis) as shown in below .  
dm/dt = AkpisS/h 
A = Membrane area 
k = Membrane permeability and h = Membrane thickness. 
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 More recently, ALZA Corporation has developed several other controlled release 
technology platforms based on the original concept of osmosis across a semipermeable 
membrane. OROS Push-Pull technology has proven to be very useful for delivering 
compounds of very high or very low solubility such as Oxybutynin chloride and 
Nifedipine. 
Ion Exchange resins 
The idea of using ion exchange resins for controlled drug delivery was adapted 
from analytical and protein chemistry. Resins are water insoluble materials containing 
anionic groups such as amino or quaternary ammonium groups, cationic groups such as 
carboxylic groups, or sulfonic groups in repeating positions on the resin chain. A drug 
resin complex is formed by prolonged exposure of drug to the resin. 
 Theoretically this controlled delivery approach is relatively immune to the 
conditions of the GI tract because an ionic environment is required to displace the drug 
from the resin. Biphetamin, a capsule containing equal quantities of amphetamine and 
dextro amphetamine complexed to a sulfonic acid cation exchange resin, has been used as 
an antiobesity drug and for behavior control in children. 
 Further improvement of the ion exchange type of delivery system is illustrated by 
the development of the Pennkinetic system. In this system, drug containing resin granules 
is first treated with a polymer such as polyethylene glycol 4000 to retard the rate of 
swelling in water and then further coated with a water permeable polymer such as 
ethylcellulose to act as rate-limiting barrier to control drug release.   
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1.9. HYPERTENSION 
Hypertension or high blood pressure is a cardiac chronic medical condition in 
which the systemic arterial blood pressure is elevated. What that means is that the heart is  
having to work harder than it should to pump the blood around the body. Blood pressure 
involves two measurements, systolic and diastolic. Normal blood pressure is at or below 
120/80 mmHg.  Hypertension is the opposite of hypotension. Hypertension is classified 
as either primary (essential) hypertension or secondary hypertension; about 90–95% of 
cases are categorized as "primary hypertension," which means high blood pressure with 
no obvious medical cause. The remaining 5–10% of cases (Secondary hypertension) are 
caused by other conditions that affect the kidneys, arteries, heart or endocrine system 8, 9. 
CLASSIFICATION 
Blood pressure is usually classified based on the systolic and diastolic blood 
pressures. Systolic blood pressure is the blood pressure in vessels during a heartbeat. 
Diastolic blood pressure is the pressure between heartbeats. A systolic or the diastolic 
blood pressure measurement higher than the accepted normal values for the age of the 
individual is classified as pre Hypertension . 
 
Hypertension has several sub-classifications, including hypertension stage I, 
hypertension stage II, and isolated systolic hypertension. Isolated systolic hypertension 
refers to elevated systolic pressure with normal diastolic pressure and is common in the 
elderly. These classifications are made after averaging a patient's resting blood pressure 
readings taken on two or more office visits. Individuals older than 50 years are classified 
as having hypertension if their blood pressure is consistently at least 140mmHg systolic 
or 90 mmHg diastolic. Patients with blood pressures higher than 130/ 80mmHg with 
concomitant presence of diabetes mellitus or kidney disease require further treatment. 
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Table.No: 2 
Classification of Hypertension 
 
Classification 
Systolic pressure Diastolic pressure 
mmHg  pKa mmHg pKa 
Normal 90–119 12–15.9 60–79 8.0–10.5 
Pre 
hypertension 
120–139 16.0–18.5 80–89 10.7–11.9 
Stage 1 140–159 18.7–21.2 90–99 12.0–13.2 
Stage 2 ≥160 ≥21.3 ≥100 ≥13.3 
Isolated 
systolic 
hypertension  
≥140 ≥18.7 <90 <12.0 
 
Essential hypertension 
Essential hypertension is the most prevalent hypertension type, affecting 90–95% 
of hypertensive patients. Although no direct cause has been identified, there are many 
factors such as sedentary lifestyle, smoking, stress, visceral obesity, potassium 
deficiency (hypokalemia), obesity(more than 85% of cases occur in those with a body 
mass index greater than salt (sodium) sensitivity, alcohol intake, and vitamin D 
deficiency that increase the risk of developing hypertension. Risk also increases 
with aging, some inherited genetic mutations, and having a family history of 
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hypertension. An elevated level of renin, a hormone secreted by the kidney, is another 
risk factor, as is sympathetic nervous system over  Insulin resistance, which is a 
component of syndrome X (or the metabolic syndrome), is also thought to contribute to 
hypertension. Recent studies have implicated low birth weight as a risk factor for adult 
essential hypertension.  
Secondary hypertension  
Secondary hypertension by definition results from an identification cause. This 
type is important to recognize since it's treated differently to essential hypertension, by 
treating the underlying cause of the elevated blood pressure. Hypertension results in the 
compromise or imbalance of the patho physiological mechanisms, such as the hormone-
regulating endocrine system, that regulate blood plasma volume and heart function. Many 
conditions cause hypertension. Some are common, well recognized secondary causes 
such as renovascular hypertension and Cushing's syndrome, which is a condition where 
the adrenal glands overproduce the hormone cortisol. Hypertension is also caused by 
other conditions that cause hormone changes, such as hyperthyroidism, 
hypothyroidism, and certain tumors of the adrenal medulla (e.g., pheochromocytoma). 
Other common causes of secondary hypertension include kidney disease, obesity and 
certain prescription and illegal drugs. 
Pathophysiology 
Most of the mechanisms associated with secondary hypertension are generally fully 
understood. However, those associated with essential (primary) hypertension are far less 
understood. What is known is that cardiac output is raised early in the disease course, 
with Total Peripheral Resistance (TPR) normal over time cardiac output drops to normal 
levels but TPR is increased. Three theories have been proposed to explain this 
 Inability of the kidneys to excrete sodium, resulting in nutriuretic factors such 
as being secreted to promote salt excretion with the side effect of raising total 
peripheral resistance. 
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 An overactive renin-angiotensin system leads to vasoconstriction and retention of 
sodium and water. The increase in blood volume plus vasoconstriction leads to 
hypertension.  
 An overactive sympathetic nervous system, leading to increased stress responses. It is 
also known that hypertension is highly heritable and polygenic (caused by more than 
one gene) and a few candidate genes have been postulated in the etiology of this 
condition.  
Drug treatment in Hypertension8, 
           When lifestyle measures and supplements are not enough to cure the condition, 
medical treatment must be applied. Many different types of drugs are used, alone or in 
combination with other drugs, to treat high blood pressure. The major categories are 
• Angiotensin-converting Enzyme (ACE) Inhibitors: ACE inhibitors work by 
preventing a chemical in the blood, angiotensin I, from being converted into a 
substance that increases salt and water retention in the body. These drugs also 
make blood vessels relax, which further reduces blood pressure.  
Examples: Captopril,Ramipril 
• Angiotensin II Receptor Antagonists: These drugs act at a later step in the same 
process that ACE inhibitors affect. Like ACE inhibitors, they lower blood pressure 
by relaxing blood vessels.  
Examples: Losartan,Valsartan. 
• Beta blockers: Beta blockers affect the body's response to certain nerve impulses. 
This, in turn, decreases the force and rate of the heart's contractions, which lowers 
blood pressure.  
Examples: Atenolol,Metaprolol. 
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• Blood Vessel Dilators (Vasodilators): These drugs lower blood pressure by 
relaxing muscles in the blood vessel walls.  
Examples: Minoxidil,Hydralazine. 
• Calcium Channel Blockers: Drugs in this group slow the movement of calcium 
into the cells of blood vessels. This relaxes the blood vessels and lowers blood 
pressure.  
Examples: Amlodipine,Diltiazem 
• Diuretics: These drugs control blood pressure by eliminating excess salt and water 
from the body.  
Examples: Furosemide,Spironolactone 
• Nerve Blockers: These drugs control nerve impulses along certain nerve 
pathways. This allows blood vessels to relax and lowers blood pressure. 
Examples: Reserpine, Gaunithidine.  
Ideal Properties of an Antihypertensive  Agent 
• Controls blood pressure by acting on the pathophysiological mechanisms that raise 
blood pressure. 
• It should be effective i.e. produce significant lowering of blood pressure; both 
systolic and diastolic. 
• Early onset of action. 
• Sustained lowering of blood pressure for 24hours no early morning risk. 
• Synergistic in blood pressure lowering effects when combined with other agents. 
• Good clinical tolerability profile thus increased patient compliance. 
• Vascular protection of end organs. 
• Pleiotropic benefits. 
• Safe for long term use absence of deleterious metabolic effects. 
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• Administation indicated in hypertensive patients with associated or concomitant 
pathology.  
Fig No:2 Mechanism of action of angiotensin II receptor blockers 
 
These drugs block the action of angiotensin II at receptor level. 
They act by blocking the angiotensin II receptors of subtype1 which regulates the 
effects of angiotensin II on blood pressure, heart, on sodium and water balance. By 
blocking the receptors these drugs inhibit the actions of angiotensin II and produse the 
following effects 
 Vasodilation and consequent decrease in peripheral vascular resistance 
 Decreased retention of sodium and water due to decrease in aldosterone synthesis. 
 Decreased release of vasopressin which is an Antidiuretic hormone and a 
vasoconstrictor. All these effects leads to fall in elevated Blood pressure. 
 Decrease in cardiovascular hypertrophy. 
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2. LITERATURE REVIEW 
K. Raghuram Reddy et.al.,(2003) The objective of the present study was to develop once 
daily sustained release matrix tablets of nicorandil, a novel potas-sium channel opener used 
in cardiovascular diseases. The tablets were prepared by the wet granulation method. Etha-
nolic solutions of ethylcellulose (EC), Eudragit RL-100, Eudragit RS-100, and 
polyvinylpyrrolidone were used as granulating agents along with hydrophilic matrix 
materials like hydroxypropyl methylcellulose (HPMC), sodium car-boxymethylcellulose and 
sodium alginate. The granules were evaluated for angle of repose, bulk density, compressi-
bility index, total porosity, and drug content. The tablets were subjected to thickness, 
diameter, weight variation test, drug content, hardness, friability, and in vitro release studies. 
The granules showed satisfactory flow properties, compressibility, and drug content9. 
Chinam Niranjan Patra et.al., (2007) evaluated the objective of the present research was to 
develop a bilayer tablet of propranolol hydrochloride using superdisintegrant  sodium starch 
glycolate for the fast release layer and water immiscible polymers such as ethylcellulose, 
Eudragit RLPO and Eudragit RSPO for the sustaining layer. In vitro dissolution studies were 
carried out in a USP 24 apparatus I. The formulations gave an initial burst effect to provide 
the loading dose of the drug followed by sustained release for 12 h from the sustaining layer 
of matrix embedded tablets. In vitro dissolution kinetics followed the Higuchi model via a 
non-Fickian diffusion controlled release mechanism after the initial burst release. FT-IR 
studies revealed that there was no interaction between the drug and polymers used in the 
study10. 
C.P. Jain et.al., (2009) In this investigation fast dissolving tablets of valsartan were prepared 
using different superdisintegrants by direct compression method. FDTs were evaluated for 
physicochemical properties and in vitro dissolution. Effect of disintegrant on disintegration 
behaviour of tablet in artificial saliva, pH 5.8 was evaluated. Wetting time of formulations 
containing Crospovidone was least and tablets showed fastest disintegration. The drug 
release from FDTs increased with increasing concentration of superdisintegrants and was 
found to be highest with formulations containing Crospovidone. The release of valsartan 
from FDTs was found to follow non-Fickian diffusion kinetics11. 
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George Vamvakas et.al., (2010) Valsartan is a non-peptide, orally active and specific 
angiotensin receptor blocker with particularly high affinity for the    type I (AT1) receptor 
subtype. Diovan is available as tablets for oral administration. Absolute bioavailability for 
Diovan is 25%(range 10-35%)1. Also, the intra-subject variability is 60%1. A novel SEDDS 
based formulation for Valsartan was developed, which is a combination of Valsartan with 
high HLB oil, high HLB surfactants and co-solvent. In vitro data indicated greater release of 
the drug from the dosage form compared to Diovan tablets. It was therefore of interest to 
evaluate the formulations in an in vivo pilot clinical study against Diovan. The data indicated 
that Banner’s SEDDS based formulation for Valsartan gave higher systemic exposure and 
lower variability results compared to Diovan12. 
 
Abdel Naser Zaid et.al., (2010) assess the quality of Valzan tablet (160 mg,valsartan 
immediate release test formulation) by comparing its pharmacokinetic parameters with 
Diovan tablet (160 mg, valsartan reference formulation). Valzan tablets were prepared 
according to a dry granulation method (roll compaction). To assess the bioequivalence of 
Valzan tablets a randomized, two-way, crossover, bioequivalence study was performed in 24 
healthy male volunteers.. Based on this statistical evaluation it was concluded that the test 
tablets (Valzan) is well formulated, since it exhibits pharmacokinetic profile comparable to 
the reference brand Diovan13. 
S. Indumathy et. al., (2010) evaluated  valsartan for its action on inflammation using 
plethysmograph method i.e. carageenin induced paw edema model. It was reported that 
angiotensin II generated from plasma had various effects including inflammation. It 
stimulates the release of pro inflammatory cytokines, activates Nuclear factor kappa B (NF –
kB), increases oxidant stress, suppress nitric oxide synthesis and behave as an inflammatory 
molecule. It also induces inflammation through the production of reactive oxygen species, 
adhesion molecules, and inflammatory cytokines such as chemo attractant protein-1(MCP-
1).our study showed that the tested drugs of angiotensin antagonists at a dose of 10mg/Kg 
possessed significant anti inflammatory activity14.  
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Parikh Bhavik Anjankumar et.al., (2010)   design and evaluate mucoadhesive bi-layered 
buccal devices comprising a drug containing mucoadhesive layer and a drug free backing 
membrane. Bi laminated films composed of mixture of drug (Valsartan) and chitosan, with 
hydroxylpropylmethylcellulose (15 cps) and backing layer (ethyl cellulose). Films were 
fabricated by solvent casting technique and were evaluated for thickness, drug content 
uniformity, bio-adhesion strength, percent, swelling index, folding endurance and in vitro 
drug release. A combination of chitosan and hydroxylpropylmethylcellulose (1:1) using 
propylene glycol (50% by weight of polymer) as plasticizer gave promising results. The 
optimized film exhibited an In vitro drug release of approximately 90% in 5 hrs along with 
satisfactory bio-adhesive strength15. 
 
K. Venkates Kumar et.al., (2010) worked out an attempt to improve the solubility and 
dissolution rate of a poorly soluble drug, Valsartan by solid dispersion method using 
skimmed milk powder as carrier. Four different formulations were prepared with varying 
drug: carrier ratios viz.1:1, 1:3, 1:5 and 1:9 and the corresponding physical mixtures were 
also prepared. The formulations were characterized for solubility parameters, drug release 
studies and drug-polymer interactions by using phase solubility studies, dissolution studies; 
XRD analysis, FTIR spectrum, TLC analysis and UV overlay spectra. All the formulations 
showed marked improvement in the solubility behavior and improved drug release. 
Formulation containing drug:polymer ratio of 1:9 showed the best release with a cumulative 
release of 81.60% as compared to 34.91 % for the pure drug. The interaction studies showed 
no interaction between the drug and the carrier16.  
 
Carlos Eduardo De Matos Jensen et. al., (2010) Valsartan, a water-insoluble drug, is 
mainly used in the treatment of hypertension  with reduced oral bioavailability. The aim of 
work was to develop a valsartan:β-cyclodextrin (VAL:β-CD) pharmaceutical composition in 
order to improve its water solubility and bioavailability. The VAL:β-CD complexes were 
prepared by the kneading, solid dispersion and freeze-drying methods, of which the freeze-
drying method(FDY) was found to be the best to prepare an inclusion complex. A physical 
mixture PM was also prepared. Complexes were characterized by thermal analysis, Fourier 
transformed- infrared (FTIR) spectroscopy, Powder X-ray diffractometry, intrinsic 
dissolution and NMR (2D-ROESY). Phase-solubility analysis showed AL-type diagrams  
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with β-cyclodextrin (β-CD). Micro calorimetric titrations suggested the formation of 
1:1inclusion complex between VAL and β-CD. The apparent stability constants 
K1:calculated from phase-solubility plots were 165.4 M-1 (298 K), 145.0 M-1 (303 K) 
and111.3 M-1 (310 K)17. 
 
D. Srinivas et.al., (2011) The purpose of the present work is to formulate and evaluate of 
Valsartan film coated tablets. In order to obtain the best optimized product, eight different 
formulations were developed using diluents, binder, glidant, lubricant, and different 
concentrations of superdisintegrant. Tablets were formulated by direct compression, slugging 
and wet granulation techniques. Various pre-compressional parameters like bulk density, 
tapped density, compressibility index and Hausner’s ratio and post compressional parameters 
like weight variation, thickness, hardness, friability,disintegration time, and drug release 
were studied. Comparatively granulation techniques exhibited the good powder flow than 
direct compression technique. The formulation F-7 was showed good drug release and 
selected as an optimized formulation and it was concluded that superdisintegrant 
concentration, granulation technique, binder, and lubricants plays a key role in the 
formulation developmentand optimizing the immediate release tablet of Valsartan 
formulation18. 
Agnivesh R. Shrivastava et.al., (2011) present work undertaken was to enhance the 
solubility and dissolution rate of valsartan a poorly water soluble antihypertensive, by 
preparation of solid dispersion granules which would additionally allow easy compression 
into tablets. The dispersion granules were prepared using a hot melt granulation technique 
which involved preparation of a homogenous dispersion of valsartan in gelucire-50/13 melt, 
followed by its adsorption on to the surface of aeroperl-300pharma®, an inert adsorbent. The 
formulation was further characterized by FTIR, DSC, XRD and SEM analysis. FTIR 
spectrum revealed some drug excipient interactions. DSC and XRD data indicated the 
retention of amorphous form of valsartan. The in-vitro dissolution rate of these tablets was 
significantly better in comparison with marketed formulation19. 
P. Mahajan et.al., (2011)The present study was aimed to develop antihypertensive sustained 
release matrix tables of valsartan Angiotensin II receptor antagonist, using 
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hydroxypropylmethylcellulose alone and in combination with ethyl cellulose as the matrix 
material in different proportion by wet granulation method. The granules were evaluated for 
angle of repose,  bulk density and Compressibility index. The tablets were subjected to 
weight variation test, drug content, hardness, friability, and in vitro release studies. The 
granules showed satisfactory flow properties, compressibility, and all the tablet formulations 
showed acceptable pharmacotechnical properties. The formulated tablets also compared with 
a marketed product. In vitro dissolution studies indicate that EC significantly reduced the rate 
of drug release compared to HPMC. But no significant difference was observed in the release 
profile of matrix tablets made by higher percentage of EC. The result of dissolution study 
indicate that the formulation prepared by low viscosity grade HPMC (H1and H2) showed 
maximum drug release up to 8 hrs and high viscosity grade HPMC and EC formulation (H3 
to H6) showed upto 12 hrs20. 
 
M. Soumya et.al., (2011) developed and optimized bilayered sustained release matrix tablets 
of Valsartan. The tablets contained an immediate releasing layer with the loading dose of the 
drug and a sustaining layer with maintenance dose of drug prepared by wet granulation 
method. The immediate releasing layer is directly compressed on to the sustaining layer. 
Sodium starch glycholate was used as super disintegrant and Eudragit RSPO and Eudragit 
RLPO were used as polymers. The drug polymer interaction was investigated by FTIR and 
DSC and their results directed further course of formulation. Valsartan tablets were evaluated 
for various post compression parameters like Tablet hardness, Friability, Weight variation, 
Drug content and In vitro dissolution. The results were found to be within the acceptable 
limits. A 3
2 
full factorial design was applied to systematically optimize the drug release 
profile. The amounts of Eudragit RSPO (X1) and Eudragit RLPO (X2) were selected as 
independent variables. The time required for 90% drug dissolution was selected as dependent 
variable21  
K. Anjan Mahapatra et.al., (2011) Solid dispersions (SDs) and physical mixtures (PMs) of 
valsartan in β-cyclodextrin (β-CD), hydroxypropyl β-cyclodextrin(HP β-CD), and polyvinyl 
pyrollidone (PVP K-30)  were prepared to increase its solubility characteristics. The drug 
formulations were characterized in the solid state by Fourier transform infrared spectroscopy 
(FTIR) and differential scanning  calorimetry (DSC). By these physical determinations, 
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drug–polymer interactions were found. Both the solubility  and the dissolution rate of the 
drug in these formulations were increased. Drug contents were determined by UV 
spectrophotometry at a λmax of 249.5 nm. The phase solubility behavior of valsartan in 
various concentrations of β-CD, HP β-CD, and PVP K-30 (0.25–1.0% w/v) in distilled water 
was obtained at 37 ± 2 °C. The dissolution of valsartan is increased with increasing amounts 
of the hydrophilic carriers (i.e., β-CD, HP β-CD, and PVP K-30). The SDs of valsartan with 
β-CD and HP β-CD were prepared at 1:1, 1:3, and 1:5 drug/carrier ratios by a kneading 
method, and PVP K-30 SDs were prepared at the same ratios (i.e., 1:1, 1:3 and 1:5 
drug/carrier) by a lyophilization technique. The FTIR spectroscopic studies show the stability 
valsartan and the absence of well-defined drug–polymer interaction22.  
Mandadi Sunitha et.al., (2011) establish Bilayer tablets containing combination of valsartan 
as sustained release and hydrochlorothaiazide as immediate release layer. Sustained release 
were prepared by wet granulation method using different viscosity grades of 
HPMC(HPMCK4M and HPMCK50M) as polymers and immediate release were prepared by 
wet granulation method using superdisintergrants such as crospovidone and croscarmellose 
sodium. The tablets were evaluated for physiochemical properties. All the values were found 
to be within the limits. In vitro release studies were carried out by USP type-2 paddle 
apparatus. The results showed that combinations of polymers namely HPMCK4M and 
HPMCK50M in sustained layer can control the release of drug. The line of best fit obtained 
was first order release kinetics(R=0.998)and Hixon-Crowell model(R=0.995)Based on 
Korsmeyer-peppas model, the drug release data further analyzed for curve fitting and the 
results confirmed that the formulation followed non-fickian diffusion kinetics23.  
KPR. Chowdary et.al., (2011)  The objective of the study is to evaluate the individual main 
and combined (or interaction) effects of β cyclodextrin (βCD) and surfactant (Poloxamer 
407) on the dissolution rate of valsartan from CD complexes and from their tablet 
formulations in a series of 22 factorial experiments. Solid inclusion complexes of Drug- βCD 
were prepared with and without Poloxamer 407 by kneading method as per 22-factorial 
design and were evaluated for dissolution rate and efficiency. The feasibility of formulating 
valsartan- βCD - Poloxamer 407 solid inclusion complexes into tablets was also evaluated. 
To evaluate the individual and combined effects of βCD and Poloxamer 407 on the 
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dissolution rate of valsartan tablets, tablets each containing 40 mg of valsartan were 
formulated employing inclusion complexes of drug- βCD - Poloxamer 407 as per 22 factorial 
design. All the prepared tablets were evaluated for hardness, friability and disintegration time 
and dissolution rate of valsartan24. 
 
Sh. Lakade et.al., (2011) The  present study aimed  to develop hydrophilic polymer (HPMC) 
and hydrophobic polymer (Ethyl cellulose) based Nicorandil matrix sustained release tablet 
which can release the drug up to time of 24 hrs in predetermined rate. The formulation of 
Nicorandil matrix tablet was prepared by the polymer combination in order to get required 
theoretical release profile. The influence of hydrophilic and hydrophobic polymer and 
granulation technique on Nicorandil was studied. The formulated tablet were also 
characterized by physical and chemical parameters, The in-vitro release rate profile should 
the higher concentration of F2 polymer in tablet, the combination of hydrophilic and 
hydrophobic combination showed less result than use of alone25.  
 
G. Raghavendra rao et. al., (2011) develop sustained release matrix tablets of water soluble 
Tramadol hydrochloride using different polymers viz. Hydroxy propyl methyl cellulose 
(HPMC) and natural gums like Karaya gum (KG) and Carrageenan (CG). Varying ratios of 
drug and polymer like 1:1 and 1:2 were selected for the study. After fixing the ratio of drug 
and polymer for control the release of drug up to desired time, the release rates were 
modulated by combination of two different rates controlling material and triple mixture of 
three different rate controlling material. After evaluation of physical properties of tablet, the 
in vitro release study was performed in 0.1 N HCl pH 1.2 for 2 hrs and in phosphate buffer 
pH 6.8 up to 12 hrs. The effect of polymer concentration and polymer blend concentration 
were studied. Different ratios like 80:20, 60:40, 50:50, 40:60 and 20:80 were taken. 
Dissolution data was analyzed by Korsmeyer-Peppas power law expression and modified 
power law expression. It was observed that matrix tablets contained polymer blend of 
HPMC/CG were successfully sustained the release of drug upto 12 hrs26. 
 
Gulam Irfani et.al., (2011) In the present work, Transdermal drug delivery of valsartan were 
formulated in different concentration (10%, 20% and 30% ) of glycerin as plasticizer and a 
blend of two in different concentrations of polymers (PVPK30, HPMC and Eudragit RS 100) 
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were formulated by solvent casting method. Drug polymer interaction study was carried out 
using FTIR. Other characteristics were confirmed by XRD and SEM studies. The formulated 
valsartan patches exhibited good physicochemical characteristics. In-vitro diffusion studies 
were performed in phosphate buffer pH 7.4 at λ max 260nm, by using cellophane membrane 
(0.45µ) in an artificial Keshary chein diffusion cell. In this study the results indicates, as 
increase in the concentration of glycerin, increases the diffusion rate of valsartan patches. 
Among polymers, the combination of Eudragit RS 100 with HPMC had increased diffusion 
rate. Various pre-compressional parameters like bulk density, tapped density, compressibility 
index and Hausner’s ratio and post compressional parameters like weight variation, 
thickness, hardness, friability,disintegration time, and drug release were studied. 
Comparatively granulation techniques exhibited the good powder flow than direct 
compression technique.. The formulation F-7 was showed good drug release and selected as 
an optimized formulation and it was concluded that superdisintegrant concentration, 
granulation technique, binder, and lubricants plays a key role in the formulation development 
and optimizing the immediate release tablet of Valsartan formulation27. 
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3. AIM AND OBJECTIVE 
To design, formulate and evaluate sustained release tablets of Valsartan sodium 
which is expected to deliver the drug in controlled and sustained release manner with 
reduce frequency of drug administration, reduce GI tract side effects and improve patient 
compliance. 
The half life of Valsartan is about 5-8 hrs. So a controlled release formulations of 
Valsartan would increase the length of time release in which Valsartan acheives an 
effective concentration in the body. 
The present work is aimed at preparation and evaluation of Sustained Release 
matrix tablets of Valsartan sodium using different polymers.  
To sustain the release and maintain the therapeutic concentration. by reducing the 
dose to 160 mg. To formulate and evaluate matrix tablets of Valsartan to sustain the 
release of drug for 12 hrs. Evaluation of optimized tablets. To improve the oral 
bioavailability and to reduce the dose dependent toxicity there is a need for the 
development of sustained-release formulations. 
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4. PLAN OF WORK 
The following experimental protocol was therefore designed to allow a systemic 
approach to the study. 
1. Selection of drug and excipients. 
2. Identification of drugs by FTIR 
3. Preformulation study 
4. Compatibility study 
5. Preparation of standard curve 
6. Formulation development 
In Process Evaluation 
 Angle of  Repose 
 Apparent Bulk Density 
 Tapped Density 
 Loss on drying 
 Hausner’s ratio 
 Carr’s index. 
Evaluation of Final Product 
 Tablet thickness 
 Tablet hardness 
 Friability 
 Weight variation 
 Disintegration. 
7. In-vitro dissolution study 
8. Stability studies 
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MATERIALS AND METHODS 
Table No: 3    
5.1 Materials used 
                                                                 
 
 
 
 
 
 
Table 5.2 List of equipments used in this study 
S.NO. Equipment                         Company 
1 16 station Compression 
Machine 
Cadmach Machinery, 
Ahmedabad. 
2 Balance Mettler Toledo, Germany. 
3 Hardness Tester Pharma test, Ahmedabad. 
4 Dissolution Apparatus, USP Electrolab, Mumbai. 
5 UV-Visible Spectrophotomter Varian Cary C50 Conc, 
Germany.  
6 Friability Tester Electrolab, Mumbai. 
7 Tap Density Tester (USP) Electrolab, Mumbai. 
8 Vernier Calipers Mitutoyo, Japan. 
 
S.No. Chemicals Company 
1 Valsartan  sodium Dr Reddys laboratories, Hyderabad 
2 HPMC Oxford Laboratories, Mumbai 
3 Kollidon Indian Research Products, Chennai 
4 Ethyl cellulose Oxford  Laboratories, Mumbai 
5 Talc S.D. Fine Chem. Ltd, Mumbai 
6 Magnesium stereate S.D. Fine Chem. Ltd, Mumbai 
7 Micro crystalline Cellulose S.D. Fine Chem. Ltd, Mumbai 
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5.3. DRUG PROFILE 
Valsartan  sodium28 
Valsartan is a nonpeptide, orally active, and specific angiotensin II receptor blocker acting 
on the AT1 receptor subtype. 
1. Chemical Name : Valsartan is chemically described as N-(1-oxopentyl)- 
    N-[[2'-(1H-  tetrazol-5-yl) [1,1'-biphenyl]-4-yl]methyl]- 
    L-valine. 
2. Molecular Formula : C24H29N5O3 
3. Molecular weight    : 435.5 
4. Chemical Structure     : 
 
5. Category  : Anti hypertensive 
6. Appearance  : Valsartan is a white to practically white fine powder 
7. Solubility             : It is soluble in ethanol and methanol and slightly soluble  
      in water. 
8. Melting Point  : The melting point was found to be  1780C. 
9. Storage  : Store at 25°C Protect from moisture 
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Pharmacokinetics 
1. Dose    : 160 mg daily twice  
2. Onset of action                : 3hrs 
3. Volume of distribution   : The volume of distribution is approximately 17 L. 
4. Excretion      : Valsartan, when administered as an oral solution,  
      is primarily recovered in feces about 83% of dose  
      and urine  about 13% of dose. 
5. Plasma Protein binding    : 95% bound to plasma proteins 
6. Bioavailability             : The systemic bioavailability is approximately 46% 
7. Elimination half life       : The plasma elimination half-life is approximately 
   5-8 hrs. 
8. Mechanism of Action : Angiotensin II is formed from angiotensin I in a  
reaction catalyzed by angiotensin-converting enzyme 
(ACE, kininase II). Angiotensin II is the 
principal pressor agent of the renin-angiotensin system, 
with effects that include vasoconstriction, stimulation of 
synthesis and release of aldosterone, cardiac stimulation, 
and renal reabsorption of sodium. Diovan (valsartan) 
blocks the vasoconstrictor and aldosterone-secreting 
effects of angiotensin II by selectively blocking the 
binding of angiotensin II to the AT1receptor in many 
tissues, such as vascular smooth muscle and the adrenal 
gland. Its action is therefore independent of the pathways 
for angiotensin II synthesis. 
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5.4 EXCIPIENT PROFILE 
5.4.1 HYDROXY PROPYL METHYL CELLULOSE 29 
Hydroxy propyl methylcellulose is mixed Alkyl hydroxyl alkyl cellulose ether and may 
be regarded as the propylene glycol ether of methylcellulose. 
1. Chemical Name :  Cellulose, 2-hydroxypropyl methyl ether 
2. Synonyms  : Methyl Hydroxy Propyl Cellulose, Propylene  
    glycol ether of methylcellulose, Culminal  
    HPMC. 
3. Structural Formula: 
OR
CH2OR
O
OO
O
O
OR
OR
OR
CH2OR
Where R is H, CH3 or CH3-CH(OH)-CH2
 
4. Physical and chemical properties  
5. Molecular weight : 10,000 - 15,00,000 
6. Color : White to creamy-white  
7. Nature : Fibrous or granular  powder 
8. Odour  : Odourless 
9. Taste  : Tasteless 
10. Density  : 0.3-1.3 g/ml 
11. Specific gravity  : 1.26 
12. Solubility  : Soluble in cold water, practically insoluble in  
    Chloroform, ethanol (95%) and ether but  
    Soluble in mixture of ethanol and  
      Dichloromethane.          
13. Melting point                           :  190-200 °C,                                                                                                                                    
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14. Functional Category  
             Coating agent, film-forming, rate-controlling polymer for sustained release, 
stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
15. Application 
            In oral product HPMC is primarily used as tablet binder, in film coating and as 
an extended release tablet matrix. Concentration between 2-5% w/w may be used as a binder 
in either wet or dry granulation process. High viscosity grade may be used to retard the release 
of water-soluble drug from a matrix. 
             HPMC is widely used in oral and topical pharmaceutical formulation. Concentration 
of 0.45-1% w/w may be added as a thickening agent to vehicle for eye drop and artificial tear 
solution. HPMC is used as an adhesive in plastic bandage and as a wetting agent for hard 
contact lenses. It is widely used in cosmetics and food products. 
              In addition, HPMC is used as an emulsifier, suspending agent and stabilizing agent in 
topical gels and ointments. As a protective colloid, it can prevent droplets and particle from 
coalescing or agglomerating thus, inhibiting the formation of sediments. 
16. Stability and storage 
 It is stable although it is slightly hygroscopic. The bulk material should be stored in an 
airtight container in a cool and dry place. Increased in temperature reduces the viscosity of the 
solution. 
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5.4.2    Vinyl pyrrolidone vinyl acetate 30 
Poly vinylacetate/Povidone based polymer (Kollidon SR) is a relatively new extended 
release matrix excipient. It consists of 80% Poly vinyl acetate and 19% Povidone in a physical 
mixture, stabilized with 0.8% sodium lauryl sulfate and 0.2% colloidal silica.  
1. Synonyms                   :    E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-        
pyrrolidinyl)ethylene]; polyvidone; poly vinyl pyrrolidone;   
PVP; 1-vinyl-2-pyrrolidinone polymer. 
2. Chemical name :   Vinylpyrrolidone-vinyl acetate 
3. Description  :  It is a tasteless, free-flowing, non-hygroscopic, white  
      powder. 
4. Functional Category :  Direct compressible grade sustained release matrix  
      former. 
5. Angle of Repose :  21° 
6. Bulk Density  :  0.37 g/ml 
7. Tapped Density :  0.44 g/ml 
8. Hausner’s Ratio :  1.13 
9. Mean Particle Size :  Approx. 100 µm 
10. Uses   : It can be easily applied for controlled release properties 
      by direct compression. It favours the development and  
      manufacture of Sustained release tablets by its high dry  
      binding capacity and the superb flow properties. It offers  
      a reliable sustained release characteristic independent of  
      the drug used. By applying low compression force  
                                       floating tablets with longer residence time in the stomach  
                                       can be achieved. 
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5.4.3 Ethyl cellulose 31 
Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer of β-anhydro 
glucose units joined together by acetal linkages. 
1. Synonyms  :  Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
2. Description  : It is a tasteless, free-flowing, white to light tan-colored  
  powder. 
3. Functional Category : Coating agent; flavoring fixative; tablet binder; tablet  
      filler; viscosity-increasing agent. 
4. Solubility               : It is practically insoluble in glycerin, propylene glycol,  
   and water. Ethylcellulose that contains less than 46.5% of 
ethoxyl groups is freely soluble in chloroform, methyl acetate, 
and tetrahydrofuran, and in mixtures of aromatic hydrocarbons 
with ethanol (95%). Ethylcellulose that contains not less than 
46.5% of ethoxyl groups is freely soluble in chloroform, 
ethanol (95%), ethyl acetate, methanol, and toluene. 
5. Stability and Storage: It is a stable, slightly hygroscopic material. It should be  
stored at a temperature not exceeding 32°C (90°F) in a dry area 
away from all sources of heat. It should not be stored next to 
peroxides or other oxidizing agents. 
6. Safety   :  It is generally regarded as a nontoxic, nonallergenic, and  
nonirritating material. It is not metabolized following oral 
consumption and is therefore a noncalorific substance. 
7. Uses   : It is used in the microencapsulation (10-20% w/w). 
a. As a sustained-release tablet coating (3-20% w/w). 
b. It can be used for tablet coating and tablet granulation  
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5.4.4 Microcrystalline cellulose32 
Microcrystalline cellulose is purified, partially depolymerized cellulose. 
1. Synonyms  : Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG;  
crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel; 
Pharmacel; Tabulose; Vivapur. 
                     
2. Description  : It occurs as a white, odorless, tasteless, crystalline powder  
     composed of porous particles. 
3. Grades  : Avicel PH-101, PH-102, PH-103; Emcocel 50M,  90M;  
      Vivapur 101, 102. 
4. Functional Category: Adsorbent; suspending agent; tablet and capsule diluent;                          
      tablet disintegrant. 
5. Solubility  : Slightly soluble in 5% w/v sodium hydroxide solution;      
practically insoluble in water, dilute acids, and most organic 
solvents. 
6. Melting point  : Chars at 260-270°C. 
7. Stability and Storage: It is a stable though hygroscopic material. The bulk  
material should be stored in a well-closed container in a    cool, 
dry place. 
8. Safety   : It is a relatively nontoxic and nonirritant material. 
9. Uses   : It is widely used as a diluent (20 – 90 %w/w). 
a. As a tablet disintegrant (5-15% w/w). 
b. It can be used as an adsorbent, antiadherent (20-   
90%w/w). 
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5.4.5 Talc 33 
Talc is a purified, hydrated and  magnesium silicate. 
1. Synonyms  : Altalc; E553b; Hydrous magnesium calcium silicate;  
Hydrous magnesium silicate; Luzenac Pharma; Magnesium 
hydrogen metasilicate; Magsil Osmanthus; Magsil Star; 
Powdered talc; Purified French chalk; Purtalc; Soapstone; 
Steatite; Superiore. 
2. Description  : Talc is a very fine, white to grayish-white, odorless,  
impalpable, unctuous, crystalline powder. It adheres readily to 
the skin and is soft to the touch and free from grittiness. 
3. Functional Category : Anticaking agent; glidant; tablet and capsule diluent;  
     tablet and capsule lubricant. 
4. Solubility  : Practically insoluble in dilute acids and alkalis, organic  
     solvents, and water. 
5. Stability and Storage: Talc is a stable material and may be sterilized by heating  
at 160°C for not less than 1 hour. It may also be sterilized by 
exposure to ethylene oxide or gamma irradiation. It should be 
stored in a well-closed container in a cool, dry place. 
6. Safety   : Talc is used mainly in tablet and capsule formulations. It  
is not absorbed systemically following oral ingestion and is 
therefore regarded as an essentially nontoxic material. However, 
intranasal or intravenous abuse of products containing talc can 
cause granulomas in body tissues, particularly the lungs. 
Contamination of wounds or body cavities with talc may also 
cause granulomas; therefore, it should not be used to dust 
surgical gloves. Inhalation of talc causes irritation and may 
cause severe respiratory distress in infants. 
7. Incompatibilities : Incompatible with quaternary ammonium compounds. 
8. Uses   : Talc can be used in oral solid dosage formulations as a  
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lubricant and diluent. However, it is widely used as a 
dissolution retardant in the development of controlled-release 
products. It is also used as a lubricant in tablet formulations; in 
a novel powder coating for extended-release pellets; and as an 
adsorbent. In topical preparations, talc is used as a dusting 
powder, although it should not be used to dust surgical gloves. 
Talc is additionally used to clarify liquids and is also used in 
cosmetics and food products, mainly for its lubricant 
properties. 
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5.4.6 Magnesium Stearate 34 
1. Synonyms  : Magnesium octadecanoate; Octadecanoic acid, magnesium   
     salt; Stearic acid, magnesium salt. 
2. Functional Category : Tablet and capsule lubricant. 
3. Description  : It is a very fine, light white, precipitated or milled,  
impalpable powder of low bulk density, having a faint odor of 
stearic acid and a characteristic taste. The powder is greasy to 
the touch and readily adheres to the skin. 
4. Flowability  : Poorly flowing, cohesive powder. 
5. Melting range : 117–150°C (commercial samples); 
6. Solubility  : Practically insoluble in ethanol, ethanol (95%), ether and        
  water; slightly soluble in warm benzene and warm ethanol  
 (95%). 
7. Stability and Storage: It  is stable and should be stored in a well-closed container  
      in a cool, dry place. 
8. Incompatibilities : Incompatible with strong acids, alkalis, and iron salts.  
Avoid mixing with strong oxidizing materials. It cannot be used 
in products containing aspirin, some vitamins, and most 
alkaloidal salts. 
9. Safety   : Nontoxic following oral administration. However, oral  
consumption of large quantities may produce a laxative effect or 
mucosal irritation. 
10. Uses   : It is widely used in cosmetics, foods, and pharmaceutical      
     formulations.  
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5.5. PREFORMULATION STUDY35  
Standard Graph of Valsartan Sodium  
 Accurately weighed amount of 100 mg Valsartan Sodium was transferred into a 100ml 
volumetric flask. 20 ml of 0.1N hydrochloric acid (HCl) was added to dissolve the drug and 
volume was made up to 100 ml with the same HCl. The resulted solution had the concentration 
of 1mg/ml which was labeled as ‘stock’. From this stock solution 10ml was taken and diluted 
to 100 ml with 0.1N HCl which has given the solution having the concentration of 100 mcg/ml. 
Necessary dilutions were made by using this second solution to give the different 
concentrations of Valsartan Sodium (5 to 50 mcg/ml) solutions35. 
             The absorbances of above solutions were recorded at λmax (249 nm) of the drug using 
double beam UV-Visible spectrophotometer. Standard graph was plotted between the 
concentration (on X-axis) and absorbance (on Y-axis). Similarly, standard graph was plotted 
with 6.8 pH phosphate buffer. 
Preparation of 0.1 N HCl: Accurately measured 8.5 ml of concentrated hydrochloric acid was 
added to 1000 ml of distilled water. 
Preparation of pH 6.8 phosphate buffer:  Accurately measured 50 ml of 0.2 M potassium 
dihydrogen phosphate was transferred to a 200ml volumetric flask and 22.4 ml of 0.2 M 
sodium hydroxide was added to it. Volume was made up to 200 ml with distilled water, mixed 
and pH was adjusted to 6.8 with 0.2 M sodium hydroxide.  
Preparation of 0.2 M potassium dihydrogen phosphate solution: Accurately weighed 
27.218 g of monobasic potassium dihydrogen phosphate was dissolved in 1000 ml of distilled 
water and mixed. 
Preparation of 0.2 M sodium hydroxide solution: Accurately weighed 8 g of sodium 
hydroxide pellets were dissolved in 1000 ml of distilled water and mixed. 
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Table No: 5 Standard Graph of Valsartan Sodium 
 
Graph No: 1 Standard graph of Valsartan Sodium 
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S. No CONCENTRATION(µg/ml) ABSORBANCE 
1 5 0.159 
2 10 0.208 
3 15 0.318 
4 20 0.428 
5 25 0.512 
6 30 0.605 
7 35 0.718 
8 40 0.860 
9 45 0.932 
10 50 1.009 
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FTIR Spectra of Valsartan Sodium
The FTIR analysis of Valsartan
identification. The FTIR spectra for pure drug and with other excepients was obtained by 
placing the drug directly into the 
wave number region of 4000-
 
Graph No: 2 FTIR 
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Graph No: 3 FTIR Spectrum of Valsartan along 
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Graph No: 4 FTIR Spectrum of Valsartan along with Vinylpyrolidone vinyl 
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Graph No: 5 FTIR 
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6. FORMULATION  
6.1. Preparation of tablets 
The hydrophilic matrix tablets were prepared by either direct compression or wet 
granulation technique. In the direct compression, sustained-release matrix tablets were 
formulated to contain 160 mg of Valsartan sodium. The drug polymer ratio was developed to 
adjust drug release as per theoretical release profile and to keep total weight of tablet constant for 
all the fabricated batches under experimental conditions of preparation. Then add 
Microcrystalline cellulose was incorporated as filler excipients to maintain the tablet weight 
constant. Powder were mixed and lubricated with 1% (W/W) magnesium stearate and then 
directly compressed on a sixteen station compression machine tablet machine at a tablet weight 
of 350 mg, with a flat, non-beveled punch of 12-mm diameter.  
In the wet granulation technique, 160 mg of Valsartan sodium and add each of the polymers 
(HPMC, Vinyl pyrolidone vinyl acetate and Ethyl cellulose) in the ratio as 1:0.25, 1:0.50 and 
1:0.75 were granulated with an Polivinyl pyrolidone (Binder). Granulates were passed through 
an 18 mesh screen and dried at 40°C for 2 hours. The dried granulate was mixed with other 
formulation components Micro crystalline cellulose (Diluent), 1.6 mg Magnesium stearate and  
Talc. Then compressed into flat tablets of 12 mm diameter.  
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    Table No: 6 Formulation Design of Sustained Release Tablets of Valsartan 
Sodium 
 
VS                  :  Valsartan Sodium 
HPMC            :   Hydroxy Propyl Methyl Cellulose 
EC                   :  Ethyl Cellulose 
PVP                 :  Poly Vinyl Pyrrolidone 
MCC                : Micro Crystlline Cellulose 
MS                   : Magnesium Stearate   
All the quantities are taken in mg. 
 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
VS 160 160 160 160 160 160 160 160 160 
HPMC 40 80 120 - - - - - - 
KOLLIDON - - - 40 80 120 - - - 
EC - - - - - - 40 80 120 
PVP 8 8 8 8 8 8 8 8 8 
MCC 137.2 97.2  57.2 137.2  97.2 57.2 137.2 97.2 57.2 
MS 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
TALC 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 
Total 350 350 350 350 350 350 350 350 350 
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7. EVALUATION STUDIES 
7.1. IN PROCESS EVALUATION OF GRANULES36 
1. Angle of repose 
2. Determination of bulk density and tapped density 
3. Carr’s index 
4. Hausner’s ratio 
 
7.2. EVALUATION OF TABLETS37 
1. Thickness 
2. Hardness 
3. Friability test 
4. Weight variation test 
5. Disintegration 
6. In-vitro dissolution 
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7.1. In Process Evaluation of Granules 
a)   Angle of Repose 
             The angle of repose of granules was determined by the funnel-method. The accurately 
weighed granules were taken in a funnel. The height of the funnel was adjusted in such a manner 
that the tip of the funnel just touched the apex of the heap of the granules. The granules were 
allowed to flow through the funnel freely onto the surface. The diameter of the powder cone 
measured and angle of repose was calculated using the following equation . 
                                                  Tan θ  = h/r 
  Where, 
  h and r are the height and radius of the powder cone, θ is the angle of repose 
Table No: 7 Relations between Angle of Repose and Flow of the Particles 
Angle of repose  (degrees) Type of flow 
< 25 Excellent 
25-30 Good 
30-40 Passable 
> 40 Very poor 
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Table No: 8 Angle of repose of Granules 
 
 b) Determination of Bulk Density and Tapped Density 
             An accurately weighed quantity of the granules/ powder (W) was carefully poured into 
the graduated cylinder and volume (V0) was measured. Then the graduated cylinder was closed 
with lid and set into the tap density tester (USP). The density apparatus was set for 100 tabs and 
after that the volume (Vf) was measured and continued operation till the two readings were 
equal. 
            The bulk density and the tapped density were calculated using the following formula. 
                                   Bulk density = W/V0 
                                  Tapped density = W/Vf 
S. No.  Formulation Angle of repose 
1 F1 25.49 
2 F2 26.24 
3 F3 29.05 
4 F4 26.97 
5 F5 29.25 
6 F6 32.27 
7 F7 27.86 
8 F8 28.26 
9 F9 31.23 
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                         where, W= Weight of the powder 
                                     V0 = Initial volume 
                                      Vf = Final volume 
C) Compressibility Index (Carr’s Index) 
            Carr’s index (CI) is an important measure that can be obtained from the bulk and tapped 
densities. In theory, the less compressible a material the more flowable it is. 
                                    CI = (TD-BD) x 100/TD    
                where, TD is the tapped density and  
    BD is the bulk density 
 
                                                     Table No: 9 Carr’s Index Values  
 S.No. Carr’s Index Properties 
1 5-12 Free flowing 
2 13-16 Good 
3 18-21 Fair 
4 23-35 Poor 
5 33-38 Very poor 
6 >40 Extremely poor 
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d)  Hausner’s Ratio     
             It is the ratio of tapped density and bulk density. Hausner found that this ratio was 
related to interparticle friction and, as such, could be used to predict powder flow properties. 
Generally a value less than 1.25 indicates good flow properties, which is equivalent to 20% of 
Carr’s index . 
 
Table No: 10 In Process Evaluation of Granules 
 
 
  
  
 
 
 
S. No.  Formulation 
Bulk density 
(g/cm3) 
Tapped density 
(g/cm3) 
Carr’s Index  
(%) 
Hausner’s 
ratio 
1 F1 0.214 0.451 14.74 1.17 
2 F2 0.308 0.464 15.38 1.18 
3 F3 0.276 0.522 14.28 1.16 
4 F4 0.341 0.488 12.11 1.13 
5 F5 0.324 0.476 13.82 1.16 
6 F6 0.320 0.597 15.39 1.24 
7 F7 0.264 0.532 13.24 1.11 
8 F8 0.282 0.498 16.75 1.21 
9 F9 0.362 0.567 14.32 1.19 
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7.2. Evaluation of Prepared Tablets 
1. Thickness 
               Five tablets from the representative sample were randomly taken and individual tablet 
thickness was measured by using digital vernier caliper. Average thickness and standard 
deviation values were calculated 
2. Hardness 
            Tablet hardness was measured by using Monsanto hardness tester. From each batch five 
tablets were measured for the hardness and average of six values was noted along with standard 
deviations. 
3.  Friability Test 
          From each batch, ten tablets were accurately weighed and placed in the friability test 
apparatus (Roche friablator). Apparatus was operated at 25 rpm for 4 minutes and tablets were 
observed while rotating. The tablets were then taken after 100 rotations, dedusted and reweighed. 
The friability was calculated as the percentage weight loss. 
Note: No tablet should stick to the walls of the apparatus. If so, brush the walls with talcum 
powder. There should be no capping also. 
  Percentage friability was calculated as follow 
                                 Percentage Friability = (W1 – W2) x 100/W1 
                             Where   W1 = Initial weight of the 20 tablets. 
                                          W2 = Final weight of the 20 tablets after testing. 
Friability values below 0.8% are generally acceptable. 
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 4. Weight Variation Test  
           To study weight variation individual weights (WI) of 20 tablets from each formulation 
were noted using electronic balance. Their average weight (WA) was calculated. Percent weight 
variation was calculated as follows. Average weights of the tablets along with standard deviation 
values were calculated. 
                            % weight variation = (WA–WI) x 100/ WA 
           As the total tablet weight was 350 mg, according to IP 1996, out of twenty tablets ±7.5 % 
variation can be allowed for not more than two tablets. 
           According to USP 2004, ±10% weight variation can be allowed for not more than two 
tablets out of twenty tablets. 
5. Disintegration 
Disintegration of a tablet means to break the tablet into smaller particles after swallowing 
the time required to disintegrate the tablet is called “Disintegration Time”. The rate of 
disintegration depends upon the type of tablet. The tablets which are dissolved by slow solution 
in the mouth or chewed or are to be dissolved in water before administration, do not need 
disintegration test. The test was performed for Sustained Release tablets of Valsartan Sodium  
six tablets were taken randomly from each batch and placed in USP disintegration apparatus 
baskets. Apparatus was run for 4 hr and the basket was lift from the fluid, observe whether all of 
the tablets have disintegrated . 
  STANDARDS: Out of six tablets five tablets should be disintegrate 
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Table No: 11 Evaluation of Prepared Tablets 
 
 
  
S. No.  Formulation 
Thickness 
(mm)  
Hardness 
(kg/cm2)  
Friability 
(%) 
Weight 
Variation 
(mg)  
1 F1 6.22 5.50  0.36 349.8±1.48 
2 F2 6.37 5.50 0.39 350± 0.54 
3 F3 6.14 5.58 0.12 349.6±0.41 
4 F4 6.20 5.66 0.41 348.8±1.64 
5 F5 6.08 4.25 0.54 348.6±1.14 
6 F6 6.33       4.08 0.58 349.2±0.83 
7 F7 6.13 4.12 0.34 347.2±0.12 
8 F8 6.21 5.42 0.46 348.9±0.23 
9 F9 6.25 5.31 0.51 349.3±0.39 
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6.  Invitro Drug Release Characteristics 
           Drug release was assessed by dissolution test using USP type II dissolution apparatus  
(paddle method) at 100 rpm in 900ml phosphate buffer pH 6.8 from 1 to 12 hours, maintained at 
37°C ± 0.5°C.   
An aliquot (5ml) was withdrawn at specific time intervals and replaced with the same 
volume of pre warmed (37°C ± 0.5°C) fresh dissolution medium.  
The samples withdrawn were filtered through Whatmann filter paper (No.1) and drug 
content in each sample was analyzed by UV-visible spectrophotometer at 249 nm.     
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Table No: 12 In-vitro Dissolution Profile for Formulation F1
 
    
 
Graph No: 6 Cumulative Percentage Drug Release Vs Time 
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Table No: 13 In-vitro Dissolution Profile for Formulation F2
 
 
 
Graph No: 7 Cumulative Percentage Drug Release Vs Time 
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Table No: 14 In-vitro Dissolution Profile for Formulation F3
 
 
 
Graph No: 8 Cumulative Percentage Drug Release Vs Time 
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Table No: 15 In-vitro Dissolution Profile for Formulation F4 
 
 
Graph No: 9 Cumulative Percentage Drug Release Vs Time 
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Table No: 16 In-vitro Dissolution Profile for Formulation F5 
 
 
Graph No: 10 Cumulative Percentage Drug Release Vs Time 
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Table No: 17 In-vitro Dissolution Profile for Formulation F6
 
 
 
 
 
 
 
 
 
 
Graph No: 11 Cumulative Percentage Drug Release Vs Time 
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Table No: 18 In-vitro Dissolution Profile for Formulation F7 
 
 
 
 
 
 
 
 
Graph No: 12 Cumulative Percentage Drug Release Vs Time 
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Table No: 19 In-vitro Dissolution Profile for Formulation F8 
 
Graph No: 13 Cumulative Percentage Drug Release Vs Time 
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Table No: 20 In-vitro Dissolution Profile for Formulation F9 
 
Graph No: 14 Cumulative Percentage Drug Release Vs Time 
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Table No: 21 Cumulative % Drug Release Vs Time 
 
 
 
 
 
 
Cumulative  Percentage  Drug Release 
Time 
(hrs) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 7.47 9.44 5.19 8.34 6.811 6.05 10.10 7.03 7.13 
2 10.7 18.01 14.92 15.60 16.40 15.57 16.04 14.6 15.36 
4 12.30 26.36 24.01 28.12 21.53 26.17 21.48 21.09 26.82 
6 24.07 31.42 32.66 43.20 30.32 35.04 41.08 27.90 38.50 
8 53.61 51.85 42.83 62.84 43.50 65.92 64.16 47.02 46.08 
10 70.42 74.70 70.52 86.13 59.10 80.48 84.81 79.54 77.66 
12 94.92 92.50 91.08 98.87 94.04 96.05 96.89 92.06 94.54 
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Graph No: 15 Cumulative Percentage Drug Release Vs Time (hrs) 
                    
 
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
C
u
m
u
la
ti
v
e
 %
 D
ru
g
 r
e
le
a
se
Time in hours
Chapter-8                                                                                                                   Stability studies 
Padmavathi College of Pharmacy and Research Instituite  70 
  
 
8. STABILITY STUDIES 
Stability testing 
  The purpose of stability testing is to asses the effect of temperature, humidity, 
moisture, light and other environmental factor on the quality of the drug substance or the 
final product. These results are used to establish the storage condition, test period and 
shelf life. The overages to be included in the formulation. 
 The drug may be detoriated due to physical, chemical, and microbial 
contaminants which will result in the formation of  
 1.  A toxic product 
 2 .  An inelegant product 
 3.  Reduced activity of preparation 
 The accelerated stability studies are done as described in the International 
Conference on Harmonization  (ICH) Guidelines. 
Procedure 
 The formulations were stored in an oven at 37 + 10C and 60 + 10C for a period of 
three months. The samples were analyzed for various parameters every month by 
spectrophotometer at 249 nm. 
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Table No.22 Stability studies of formulation F4 
 
  
Specification Initial 30 Days 60 Days 90 Days 
Appearance 
White round 
tablet 
White 
No change 
observed 
No change 
observed 
No change 
observed 
Average 
weight 
350 mg + 2% 
350mg 349mg 349mg 348mg 
Hardness 5.5 Kg/cm2 5.5 Kg/cm2 5.6 Kg/cm2 5.4 Kg/cm2 
Friability 0.36% 0.36% 0.35% 0.34% 
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Table No.23 DISSOLUTION STUDY 
 
 
 
Dissolution 
Medium 900ml 
pH 6.8 
Time in 
(hrs) 
Cumulative % drug release 
Initial 3 Months 
F4 F4 
1 8.34 7.12 
2 15.60 14.28 
4 28.12 27.98 
6 43.20 42.89 
8 62.84 61.11 
10 86.13 85.76 
12 98.87 97.84 
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Graph No. 16. Cumulative % drug release Vs time during stability 
studies 
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9. RESULTS AND DISCUSSION 
The procured sample of Valsartan sodium was tested for its identification by using 
FT-IR Spectra study were shown. 
The drug and excipient compatibility was done at 250C. And Relative Humidity 
was found to be 60% ± 5%The results does not show any physical change to the mixture 
after 4 weeks. Chemical compatibility was analyzed by the spectrum study. This fact 
concluded that the drug and the excipient are compatible with each other was determined 
using IR Spectra. 
Before compression of tablets all the polymers were tested with quantity of diluent 
and lubricant to observe the flow property and the amount was fixed after successive 
initial trials. 
In the present work, total nine formulations were prepared and the detailed 
composition were shown in Table No.6. The prepared pre compression blend was then 
subjected to various evaluation studies such as Angle of Repose, Carr’s Index, Hausner’s 
Ratio, Bulk density, Tapped density, etc., and the results are shown in Table No.10 
The Prepared tablets were evaluated for various parameters such as Hardness, 
Friability, Weight Variation, Thickness, In vitro drug release and these results were 
shown in Table No.11 
The study was well targeted for sustained release of Valsartan sodium all the criteria 
of drug was properly studied along with polymer property. Different parameters of tablet 
like flow property, thickness, hardness, drug content etc., were studied with results in 
successful trials. The amount of drug release in fixed duration was of more importance 
and was performed with precision and accuracy and In Vitro drug release studies. The 
utilization of Vinyl pyrrolidone vinyl acetate is to reduce the formulation cost and make it 
cost effective formulation and increase bioavailability.      
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10. SUMMARY AND CONCLUSION 
Sustained Release tablets were compressed without any problem and do not 
require any change in ratio of excipients in formulation. Results of the present study 
demonstrated that combination of both hydrophilic and hydrophobic polymers could be 
successfully employed for formulating sustained release matrix tablets of Valsartan 
Sodium. 
The drug release rate was almost similar with HPMC and plastic Vinyl 
pyrrolidone vinyl acetate   Sustained Release tablets. All the formulations have shown 
drug release in 12 hrs. The formulation F4 have been choosen as optimum preparation 
with higher drug release and enhanced bioavailability. Majority of formulations have 
released the drug by Non  Fickian diffusion.  
The formulation with Ethyl Cellulose has shown low drug release and has the 
problem of dose dumping. The formulation with HPMC has shown similar drug release 
as that of Vinyl pyrrolidone vinyl acetate  but does not follow the theoretical drug release 
profile. Micro crystalline cellulose used as a diluents does not show any effect on the 
drug release pattern. 
Optimized formulation F4 which includes Vinyl pyrrolidone vinyl acetate  has 
successfully sustained the drug release  for 12 hours and the drug release pattern was 
similar to theoretical release profile.  
FT-IR studies combined with stability studies proved the integrity of the 
developed tablets. 
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